Tango Therapeutics, Inc. (TNGX) — SEC Financial Statements & Analysis

Tango Therapeutics, Inc. (TNGX) is a pharmaceutical preparations company, incorporated in DE. Tango Therapeutics, Inc. trades on Nasdaq as: TNGX. Tango Therapeutics, Inc. (TNGX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, Tango Therapeutics, Inc. carries a market cap of $4.69B, a P/E ratio of -37.87x, a P/B ratio of 4.57x, a P/S ratio of 87.07x, an enterprise value of $4.34B, and an EV/EBITDA multiple of -32.28x. On profitability, it posts an operating margin of -253.38%, a net margin of -229.92%, a Return on Equity (ROE) of -21.34%, a Return on Assets (ROA) of -18.86%, and a Return on Invested Capital (ROIC) of -35.13%. Per share, it reports EPS of $-0.83, diluted EPS of $-0.83, free cash flow per share of $-0.96, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 121.48% year-over-year, net income growth of -15.01% year-over-year, and EPS growth of -37.31% year-over-year. On the balance sheet, it maintains a current ratio of 50.82x, a quick ratio of 49.95x, working capital of $1.01B, a debt-to-equity ratio of 0.05x, a debt ratio of 0.05, an interest coverage ratio of -15.71x, free cash flow of $-144.29M (TTM), and net debt of $-345.56M. Figures sourced from SEC EDGAR.

Market Cap

$4.69B

P/E TTM

-37.87x

EPS TTM

$-0.83

P/B TTM

4.57x

ROE TTM

-21.34%

ROA TTM

-18.86%

Debt To Equity

0.05x

Free Cash Flow TTM

$-144.29M

Net Revenue TTM Growth 1Y

121.48%

Data as of 2026-06-30 · Source: SEC EDGAR